Latest research on Prostaglandin e1

Alprostadil is produced endogenously and causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. In infants, it is used for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. In adults, it is used for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.

Latest findings

This study indicates that, although the mechanism of action of Misoprostol is unknown, impairment of rat liver mitochondrial respiratory function in chronic injury can be partially prevented or corrected by treatment with the synthetic Prostaglandin e1 derivative Misoprostol. [source, 1998]
The most recent CDC estimate is that the number of persons living with HIV disease is 650,000-900,000 (Karon et al., 1996). [source, 1998]
To avoid platelet activation, all centrifugations were done at room temperature and in the presence of 1 μM prostaglandin E1 (Alprostadil, PROSTIN VR Pediatric®; The Upjohn Co., Kalamazoo, MI). [source, 1998]
Estimates of the number who had HIV infection (but not AIDS) in 1992 range from 550,000 to 800,000 (Karon et al., 1996). [source, 1998]
In cases of ALI euphylline (250 mg iv), broad spectrum antibiotics (with coverage of anaerobics) with Prostaglandin e1 (continuous infusion starting at 5 up to 30 ng/kg/min) were added. [source, 1997]
In the MV patients with opacities on chest X-ray or CT scan euphylline, broad spectrum antibiotics and Prostaglandin e1 iv should be added. [source, 1997]
Blood was collected from the antecubital vein of healthy adult donors through a 19-gauge needle into syringes containing, as anticoagulant the thrombin inhibitor d-phenylalanyl-l-arginine chloromethyl ketone dihydrochloride (PPACK; Bachem Bioscience Inc., Philadelphia, PA) (50 nM final concentration) and supplemented, when indicated, with Prostaglandin e1 (PGE1; Sigma Chemical Co., St. Louis, MO) (20 nM final concentration) to inhibit platelet activation. [source, 1997]
High growth in Medicare home health use has been attributed to legislative changes which permitted greater involvement of proprietary firms, broadened eligibility requirements and service coverage, and to the introduction of the PPS which gave hospitals an incentive to make maximum use of post-acute home health and nursing home care to reduce length of stay (Bishop and Karon, 1988; Leader, 1986; Balinsky and Starkman, 1987; Kenney, 1991a). [source, 1993]
Although the home health benefit has been receiving increasing attention in recent years (Swan and Benjamin, 1990; Kenney and Dubay, 1992; Kenney, 1991a; Benjamin, 1986; Bishop and Karon, 1988), very little attention has been given to establishing whether service use differs in rural and urban areas. [source, 1993]
reported continuous infusion of high does Prostaglandin e1 (PGE1) with excellent clinical results in 10 patients with FHF. [source, 1988]